For the Inventor, By the Inventor

Enter assignee name

Usv Private Limited

Calculating rank

USPTO Granted Patents = 27

% Expired Patents = 81.5

CIPO Patents = 1

EPO Patents = 8

Trademarks = 2

Forward Citations = 124

Loading Chart...

Loading Chart...

80 inventors (with patents filed for the assignee):

Dhananjay Govind Sathe (7 out of 30 patents)

Divya Lal Saksena (6 out of 6 patents)

Chandrakesan Muralidharan (5 out of 5 patents)

4. Nikhil Umesh Mohe (5 out of 5 patents)

5. Kamlesh Digambar Sawant (4 out of 5 patents)

6. Harish Kashinath Mondkar (4 out of 4 patents)

7. Venkatasubramanian Radhakrishnan Tarur (4 out of 5 patents)

8. Purushottam Sharshikant Singnurkar (4 out of 4 patents)

9. Suresh Kumar Gidwani (4 out of 5 patents)

10. Tushar Anil Naik (3 out of 4 patents)

11. Rakesh Shekhawat (3 out of 3 patents)

12. Lester John Lobo (3 out of 3 patents)

13. Digamber Shripati Pawar (3 out of 3 patents)

14. Varsha Shashank Choudhary (3 out of 3 patents)

15. Yogesh Sharad Bhide (3 out of 3 patents)

Core Competencies:

Pharmaceutical Compositions

Peptide Synthesis

Modified Release

Polymorphs

Cyclodextrin

Chimeric Hormones

Analytical Methods

Sustained Release

Formulations

Process Preparation

Gram Scale Production

27 patents: Sort by Forward Citations

1. 10815265 - Process for preparation of regadenoson and polymorphs thereof (2020-10-27),

2. 9688657 - Synthesis of dabigatran (2017-06-27),

3. 9029507 - Copolymer-1, process for preparation and analytical methods thereof (2015-05-12),

4. 8865213 - Modified release pharmaceutical compositions (2014-10-21),

5. 8846614 - Process for the synthesis of 37-mer peptide pramlintide (2014-09-30),

6. 8829157 - Process for the synthesis of cyclic heptapeptide (2014-09-09),

7. 8741962 - Process for preparation of Rasagiline and salts thereof (2014-06-03),

8. 8586710 - Process for gram scale production of PEG-r-metHuG-CSF (2013-11-19),

9. 8377891 - Process for synthesis of cyclic octapeptide (2013-02-19),

10. 8298789 - Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34) (2012-10-30),

11. 8187634 - Process for the preparation of sevelamer hydrochloride and formulation thereof (2012-05-29),

12. 7964182 - Pharmaceutical compositions comprising phosphate-binding polymer (2011-06-21),

13. 7897724 - Solid phase Fmoc chemistry process to prepare peptides (2011-03-01),

14. 7846425 - Process for the preparation of sevelamer hydrochloride and formulation thereof (2010-12-07),

15. 7820409 - Chimeric human growth hormone derived from the placenta and pituitary isoform and processes for obtaining said chimera (2010-10-26),

Company Overview

Usv Private Limited is a prominent pharmaceutical company based in Mumbai, India, specializing in the development and manufacturing of a diverse range of healthcare products. The organization focuses on innovative drug formulations and delivery systems, catering to various therapeutic areas including cardiology, diabetes, and oncology. With a commitment to research and development, Usv aims to enhance patient outcomes through advanced medical solutions, leveraging its expertise in pharmaceutical sciences and technology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

27 Patents

#18 in Mumbai

#77 in India

#24,046 in the World

Usv Private Limited

Forward Citations = 124

80 inventors:

Dhananjay Govind Sathe (7 out of 30 patents)

Divya Lal Saksena (6 out of 6 patents)

Chandrakesan Muralidharan (5 out of 5 patents)

4. Nikhil Umesh Mohe (5 out of 5 patents)

5. Kamlesh Digambar Sawant (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Usv Private Limited. Retrieved from https://idiyas.com/company/usv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…